Search Results for: cnsp

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system (“CNS”), today announced that its CEO John Climaco will participate in the Virtual Investor 2022 Top Picks Conference at 11:00 a.m. ET on Wednesday, Jan. 26, 2022. As part … Continue reading “QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) to Present at Virtual Investor 2022 Top Picks Conference”

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, has closed on its previously announced private placement. The company announced that the placement was comprised of 12,105,264 shares of common stock (or prefunded warrants) and warrants at a … Continue reading “QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Closes on $11.5M Private Placement”

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, announced that CEO John Climaco will present at the upcoming H.C. Wainwright BioConnect Conference. The conference is slated for Jan. 10-13, 2022. Interested parties who have registered for the … Continue reading “QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) to Participate at H.C. Wainwright BioConnect Conference”

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system (“CNS”), has entered into securities purchase agreements with several institutional and accredited investors. The agreements outline the issue of more than 12 million shares of common stock, prefunded warrants … Continue reading “QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Announces Agreements Totaling $11.5M for Gross Proceeds”

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, has received approval from the Switzerland Ethics Committee (swissethics) — the first approval of its kind from a European ethics committee — for its study of Berubicin. Exclusive to … Continue reading “QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Announces Switzerland Ethics Committee Approval of Pivotal Berubicin Study”

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, will be presenting at the Virtual Investor Roundtable Event, scheduled for Nov. 18, 2021. The CNSP overview, presented by CNS Pharmaceuticals CEO John Climaco and chief medical officer Sandra L. … Continue reading “QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Announces Participation at Upcoming Virtual Investor Roundtable”

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system (“CNS”), today announced that it has been featured in a broadcast via NetworkNewsAudio (“NNA”), a solution that delivers additional visibility, recognition and brand awareness in the investment community via … Continue reading “QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) CEO Discusses Berubicin’s Impressive Potential in Syndicated Broadcast”

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system (“CNS”), today announced the dosing of the first patients in its Berubicin clinical development program for the treatment of recurrent glioblastoma multiforme (“GBM”), one of the most aggressive types … Continue reading “QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Doses First Group of Patients in Potentially Pivotal Trial”

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system (“CNS”), today reported its financial results for the quarter ended June 30, 2021. The company also provided a clinical update of its anti-cancer drug candidates currently in development for … Continue reading “QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Announces Q2 2021 Financial Results, Provides Business Outlook”